Entyvio is a brand-name prescription medication known as a biologic. Its active ingredient is called vedolizumab. Generic versions of biologic medications are called biosimilars. But only the ...

Entyvio is a brand-name prescription biologic drug. It contains the active ingredient vedolizumab. Biosimilars are generic versions of biologic medications, but only the brand-name version of this ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Patients with Crohn’s disease treated with IV Entyvio demonstrated considerable improvements in ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...

Takeda has announced that its subcutaneous (SC) Entyvio (vedolizumab) has been approved by the US Food and Drug Administration (FDA) as a maintenance therapy for adults with moderately to severely ...

EXTON, Pa., June 8, 2021 /PRNewswire/ — A few months after the European Medicines Agency (EMA) approved Takeda’s subcutaneous formulation of Entyvio, known as Entyvio SC, Spherix captured the initial ...

Ulcerative colitis and Crohn’s disease are types of inflammatory bowel disease (IBD) that cause irritation and inflammation in the gastrointestinal tract (GI tract). The immune system attacks the GI ...

The US Food and Drug Administration (FDA) has approved the subcutaneous (SC) administration of vedolizumab (Entyvio SC, Takeda) for maintenance therapy in adults with moderately to severely active ...

EXTON, Pa., Sept. 24, 2020 /PRNewswire/ -- The 2020 audit included in Spherix's RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (US) service focuses on a critical facet of overall ...